STTK vs DNA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
STTK · Shattuck Labs$4.46 ▼ 1.98%
DNA · Ginkgo Bioworks$7.46 ▼ 9.02%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- STTK +116.5%
- DNA -13.4%
Head to head
| Metric | STTK | DNA |
|---|---|---|
| Price | $4.46 | $7.46 |
| Change today | ▼ 1.98% | ▼ 9.02% |
| Market cap | $454.22M | $483.59M |
| Return, 3 months | -43.5% | +10.0% |
| Return, year to date | +22.2% | -10.2% |
| Return, 1 year | +119.7% | -8.7% |
| P/E (TTM) | – | – |
| P/B | 2.3 | 1.2 |
| P/E percentile vs own 5y | 10th | 30th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -100.0% | -5.7% |
| Net profit growth (YoY) | -150.6% | +49.2% |
| Gross margin | – | 69.8% |
| Operating margin | – | -202.5% |
| Net margin | – | -192.0% |
| Return on equity | -47.2% | -52.7% |
| Analyst target vs. price | +242.8% | -33.0% |
| Analyst buy share | 100% | 0% |
| RSI (14) | 35 | 37 |
| 30-day volatility | 73.9% | 137.1% |
| Max drawdown, 1 year | -50.5% | -50.2% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Sell |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DNA is the largest of the group by market value.
- STTK has returned the most over the past year.
- DNA is growing revenue fastest.
- STTK has been the calmest stock over the last 30 days.